Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IndividualfiledCriticalIndividual
Priority claimed from PCT/EP1997/000380external-prioritypatent/WO1997029126A1/fr
Publication of CA2244911A1publicationCriticalpatent/CA2244911A1/fr
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
L'invention concerne un nouveau procédé de synthèse de l'analogue Ac(1-31)-NH¿2? du peptide intestinal vasoactif (VIP) à partir de quatre fragments protégés de peptides.
CA 22449111996-02-091997-01-29Synthese d'analogue du peptide intestinal vasoactif (vip)
AbandonedCA2244911A1
(fr)
Solid phase synthesis of partially protected and free peptides containing disulphide bonds by simultaneous cysteine oxidation‐release from 2‐chlorotrityl resin
Synthesis of the 60 amino acid homeo domain and smaller fragments of the Drosophila gene regulatory protein Antennapedia by a segment synthesis-condensation approach
Facile solid-phase synthesis of sulfated tyrosine-containing peptides: Part II. Total synthesis of human big gastrin-II and its C-terminal glycine-extended peptide (G34-Gly sulfate) by the solid-phase segment condensation approach
Combined solid‐phase/solution synthesis of a 31‐residue vasoactive intestinal peptide analog: general method for repetitive coupling of fragments without isolation and purification of intermediates